170 related articles for article (PubMed ID: 17918261)
21. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
22. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer.
Lee SH; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
Lung Cancer; 2014 Aug; 85(2):175-81. PubMed ID: 24951318
[TBL] [Abstract][Full Text] [Related]
23. VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer.
Dalaveris E; Kerenidi T; Katsabeki-Katsafli A; Kiropoulos T; Tanou K; Gourgoulianis KI; Kostikas K
Lung Cancer; 2009 May; 64(2):219-25. PubMed ID: 18845357
[TBL] [Abstract][Full Text] [Related]
24. A new tumour associated antigen of non-small cell lung cancer: tumour liberated proteins (TLP)--a possible new tumor marker.
Garaci E; Sinibaldi P; Rasi G
Anticancer Res; 1996; 16(4B):2253-5. PubMed ID: 8694552
[TBL] [Abstract][Full Text] [Related]
25. Immunochemical property of human haptoglobin phenotypes: determination of plasma haptoglobin using type-matched standards.
Cheng TM; Pan JP; Lai ST; Kao LP; Lin HH; Mao SJ
Clin Biochem; 2007 Sep; 40(13-14):1045-56. PubMed ID: 17583688
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.
Lebanony D; Benjamin H; Gilad S; Ezagouri M; Dov A; Ashkenazi K; Gefen N; Izraeli S; Rechavi G; Pass H; Nonaka D; Li J; Spector Y; Rosenfeld N; Chajut A; Cohen D; Aharonov R; Mansukhani M
J Clin Oncol; 2009 Apr; 27(12):2030-7. PubMed ID: 19273703
[TBL] [Abstract][Full Text] [Related]
27. High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer.
Lu J; Wang Y; Yan M; Feng P; Yuan L; Cai Y; Xia X; Liu M; Luo J; Li L
Oncotarget; 2016 Jul; 7(27):41758-41766. PubMed ID: 27248178
[TBL] [Abstract][Full Text] [Related]
28. Protein expression and fucosylated glycans of the serum haptoglobin-{beta} subunit in hepatitis B virus-based liver diseases.
Shu H; Zhang S; Kang X; Li S; Qin X; Sun C; Lu H; Liu Y
Acta Biochim Biophys Sin (Shanghai); 2011 Jul; 43(7):528-34. PubMed ID: 21606158
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
[TBL] [Abstract][Full Text] [Related]
30. [Serum haptoglobin and alpha-1 antitrysin levels as biological evolution markers in patients with gastric and colorectal cancer].
Kovcić V; Jelić S; Filipović I; Tomasević Z
Srp Arh Celok Lek; 1994; 122(11-12):311-3. PubMed ID: 17974404
[TBL] [Abstract][Full Text] [Related]
31. Proteomic profiling identifies haptoglobin as a potential serum biomarker for steroid-resistant nephrotic syndrome.
Wen Q; Huang LT; Luo N; Wang YT; Li XY; Mao HP; Zhang L; Dong XQ; Yu XQ
Am J Nephrol; 2012; 36(2):105-13. PubMed ID: 22759352
[TBL] [Abstract][Full Text] [Related]
32. Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling.
Okano T; Seike M; Kuribayashi H; Soeno C; Ishii T; Kida K; Gemma A
Int J Oncol; 2016 Mar; 48(3):945-52. PubMed ID: 26783151
[TBL] [Abstract][Full Text] [Related]
33. Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer.
Chiappetta C; Anile M; Leopizzi M; Venuta F; Della Rocca C
Clin Chim Acta; 2013 Oct; 425():93-6. PubMed ID: 23892142
[TBL] [Abstract][Full Text] [Related]
34. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer.
Dowling P; Clarke C; Hennessy K; Torralbo-Lopez B; Ballot J; Crown J; Kiernan I; O'Byrne KJ; Kennedy MJ; Lynch V; Clynes M
Int J Cancer; 2012 Aug; 131(4):911-23. PubMed ID: 21953030
[TBL] [Abstract][Full Text] [Related]
35. Non-invasive diagnosis of pleural malignancies: the role of tumour markers.
van den Heuvel MM; Korse CM; Bonfrer JM; Baas P
Lung Cancer; 2008 Mar; 59(3):350-4. PubMed ID: 17933420
[TBL] [Abstract][Full Text] [Related]
36. Pentraxin-3 is a novel biomarker of lung carcinoma.
Diamandis EP; Goodglick L; Planque C; Thornquist MD
Clin Cancer Res; 2011 Apr; 17(8):2395-9. PubMed ID: 21257721
[TBL] [Abstract][Full Text] [Related]
37. The use of receiver operating characteristic (ROC) analysis to assess the diagnostic value of serum amyloid A, haptoglobin and fibrinogen in traumatic reticuloperitonitis in cattle.
Nazifi S; Ansari-Lari M; Asadi-Fardaqi J; Rezaei M
Vet J; 2009 Nov; 182(2):315-9. PubMed ID: 18783967
[TBL] [Abstract][Full Text] [Related]
38. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
39. Cut-off-independent tumour marker evaluation using ROC approximation.
Bitterlich N; Schneider J
Anticancer Res; 2007; 27(6C):4305-10. PubMed ID: 18214036
[TBL] [Abstract][Full Text] [Related]
40. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
